Cargando…

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?

Detalles Bibliográficos
Autor principal:	Zojer, Niklas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444516/ https://www.ncbi.nlm.nih.gov/pubmed/34548885 http://dx.doi.org/10.1007/s12254-021-00741-1

Ejemplares similares

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
por: Piñana, José Luis, et al.
Publicado: (2023)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
por: Tamariz-Amador, Luis-Esteban, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Adherence to Sars-CoV2 vaccination in hematological patients
por: Narinx, Justine, et al.
Publicado: (2022)

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies
por: Wiestner, Adrian
Publicado: (2022)

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination
por: Guven, Deniz C, et al.
Publicado: (2022)

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
por: Ni, Bin, et al.
Publicado: (2022)

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
por: Guven, Deniz C, et al.
Publicado: (2022)

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

Occurrence of Severe SARS-CoV-2 Infection in Fully Vaccinated Solid Organ Transplant Recipients
por: Marinaki, Smaragdi, et al.
Publicado: (2022)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments
por: Pfannes, Roald, et al.
Publicado: (2023)

SARS-CoV-2: To be or not to be vaccinated?
por: Beauchet, Olivier
Publicado: (2021)

Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

SARS-CoV-2 infection in fully vaccinated healthcare workers
por: Hernández Porto, Miriam, et al.
Publicado: (2022)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Ko, Humphrey H T
Publicado: (2022)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Knol, Mirjam J, et al.
Publicado: (2022)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Franco-Paredes, Carlos
Publicado: (2022)

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
por: Martinez Lopez, Joaquin, et al.
Publicado: (2022)

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
por: Aleman, Adolfo, et al.
Publicado: (2021)

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Tamariz-Amador, L.-E., et al.
Publicado: (2022)

SARS-CoV-2 Vaccine in Dialysis Patients: Time for a Boost?
por: Krueger, Karen M., et al.
Publicado: (2022)

Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer
por: Chebel, Roy, et al.
Publicado: (2021)

In Pursuit of a SARS-CoV-2 Vaccine
por: Johnson, Alton R., et al.
Publicado: (2020)

SARS-CoV2 vaccines: Slow is fast
por: Green, Douglas R.
Publicado: (2020)

Effectiveness of an Inactivated SARS-CoV-2 Vaccine
por: Wilder-Smith, Annelies, et al.
Publicado: (2021)

SARS-CoV2 vaccine boosters for India
por: Kang, Gagandeep
Publicado: (2022)

The SARS-CoV-2 vaccines: Retrospective and perspectives
por: Epaulard, Olivier
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed
por: Linares-Fernández, Sergio, et al.
Publicado: (2020)

Nursing in patients with hematological malignancies
por: Geres, Hana, et al.
Publicado: (2020)

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
por: Piñana, José Luis, et al.
Publicado: (2022)

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
por: Mohamed, Sara, et al.
Publicado: (2023)

Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma
por: Wang, Lindsey, et al.
Publicado: (2021)

Clinical characteristics of SARS-CoV-2 fully-vaccinated patients dying with COVID-19 in Italy
por: Palmieri, Luigi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upu92ku7fh8b5kigbi62ii87tm